<SEC-DOCUMENT>0001193125-11-099845.txt : 20110418
<SEC-HEADER>0001193125-11-099845.hdr.sgml : 20110418
<ACCEPTANCE-DATETIME>20110415183418
ACCESSION NUMBER:		0001193125-11-099845
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110415
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110418
DATE AS OF CHANGE:		20110415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		11764064

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B>Date of Report (Date of Earliest Event Reported):<B> April&nbsp;15, 2011 (April 15, 2011) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;15, 2011, (the &#147;effective date&#148;) ARCA biopharma, Inc. (&#147;ARCA&#148;) entered into a license agreement (the &#147;agreement&#148;) with the University of Cincinnati (the
&#147;University&#148;) to license exclusive worldwide rights to a portfolio of U.S. and international patents, which includes certain U.S. and international diagnostic patents covering genetic markers for ARCA&#146;s lead drug candidate, Gencaro
(bucindolol hydrochloride). These patents relate to genetic polymorphisms of adrenergic cardiac receptors and provide the basis for exclusive worldwide development, use and commercialization of the genetic testwhich may indicate a patient&#146;s
likely response to Gencaro as a treatment for chronic heart failure and other indications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the license
agreement, ARCA has agreed to pay the University an initial license fee of $15,000 within 60 days of the effective date, and a license maintenance fee of $15,000 beginning on the first anniversary of the effective date and continuing annually for
the term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has agreed to pay the University royalties on the net sales of genetic tests, including those related to
bucindolol. ARCA has agreed to pay a minimum royalty of beginning on the earlier of 2016 (which may be extended to 2017 subject to certain conditions), or the first year with in which there are two quarters of commercial sales, increasing two years
afterwards , and for each calendar year thereafter during the term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has agreed to make milestone payments to the
University upon the first occurrence of various milestones, including the issuance of certain U.S. patents; the first commercial revenue of licensed products covered by certain licensed patent rights; and for the achievement of net sales levels of
$500,000 of licensed products covered by certain licensed patent rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the agreement, ARCA also has the
right to issue exclusive and nonexclusive sublicenses to such rights to third parties, subject to certain terms. ARCA has agreed to pay the University a certain percentage of all non-royalty sublicense income. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has agreed to arrange for the preparation, filing, prosecution and maintenance for selected patent applications and rights.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA has also agreed to use commercially reasonable efforts to work diligently in the development, production and marketing
of licensed products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA may terminate the agreement or convert it to a nonexclusive license at any time by providing 120
days&#146; written notice to the University. In the event that ARCA is in default of any of its obligations under the agreement, the University may at its sole option, (effective 60 days following notice of default by the University and ARCA&#146;s
failure to cure said default prior to the expiration of such 60-day period): (a)&nbsp;terminate the Agreement or (b)&nbsp;convert any exclusive license to a non-exclusive license. Absent the agreement being terminated as described above, the term of
the agreement will extend to expiration of the last to expire patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A press release is attached as Exhibit&nbsp;99.1 hereto, the contents
of which are incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma licenses exclusive worldwide rights to bucindolol genetic markers,&#148; dated April&nbsp;15, 2011.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April&nbsp;15, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Senior Vice President and General Counsel</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma licenses exclusive worldwide rights to bucindolol genetic markers,&#148; dated April&nbsp;15, 2011.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g175254g13q33.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA LICENSES EXCLUSIVE
WORLDWIDE RIGHTS TO BUCINDOLOL GENETIC MARKERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, April&nbsp;15, 2011</I> &#150; ARCA biopharma, Inc.
(Nasdaq: ABIO) today announced that it has entered into a license agreement with the University of Cincinnati for exclusive worldwide rights to a portfolio of U.S. and international patents, which includes certain patents covering genetic markers
for the Company&#146;s lead drug candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride), which is being developed for the treatment of chronic heart failure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The licensed patents relate to genetic
polymorphisms of adrenergic cardiac receptors which the Company believes provide the basis for exclusive worldwide development, use and commercialization of the genetic test which may indicate a patient&#146;s likely response to Gencaro as a
treatment for multiple cardiovascular disorders. The licensed patents had been the subject of an Exclusive License Agreement between the Company and the University of Cincinnati executed in December 2009. ARCA has been awarded a patent from the U.S.
Patent and Trademark Office (March 2010) and a patent from the European Patent Office (October 2010) on methods of treating heart failure patients with bucindolol based on genetic testing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has previously entered into a commercialization and licensing agreement with Laboratory Corporation of America (LabCorp) to develop, produce, market and sell diagnostic tests in connection
with the medical prescription of Gencaro. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride) is a pharmacologically unique
beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking
beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro is well-tolerated in
patients with advanced HF. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has previously designated as a Fast Track development program the investigation of Gencaro for the
reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA
biopharma </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for heart
failure and other cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it
believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for
Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to, statements regarding the ARCA&#146;s development program potential to be the first genetically-targeted therapy for heart failure. Such statements are based on management&#146;s current
expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties
associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g175254g13q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g175254g13q33.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!%`,H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#OM6UJ:69[
M>V8QQH=I93RW_P!:LV.%I&^8DYZDTD$1D?U)K9M;4-B.0;&_A)'Z&OC$JN,J
M.4W_`%V/1]VFK(STL&+E2.0#3&LR%+8X%=$J0I(N]OW@4JP`S[4V2T1H5`8!
M%Y=O?Z5VO+8\NAE[9W.91Y[5]\4CH1W4XKJ-&U(ZA;L),":/AL=QZUCW=N6!
M*H50=,U+X;&V^F'_`$S_`*UG@95,/B53O[K*JVG!OJ=)1117U1PE/5]1CTC2
MKF_EY6%"P']X]A^)JMX:UH:_HD-^55)&RLJ+T5AUK(\5Q/X@U2W\-PR%5$;7
M-RP[8&$'XFL#X9ZB]GJEWHUQ\IDRZJ>SKPP_+^5`'I=5[^2\BM6>QMX[B<$8
MCDDV`COS@U8HH`X?4?B'>:-=&UU'P^T,P&X`7(((]0<=*T[37O$=_:I=6_AJ
M-8I%W)YMX%)'KC%<G\5/^0W9_P#7M_[,:]&TK_D$67_7O'_Z"*`.?B\>06^H
M_P!GZWI\^ES<?,[!TY[Y';WKJE8,H92"",@@\&O/?BO''LTV7`\PEUSW*\5T
MO@AYY/"%@9\[@A"D]2H)Q^E`&Z[K&C.[!549+,<`"N6F\<1W5\;#0+"75)QU
M=3LC7W+'M7/_`!#U^>\U%?#]DQV*5$P4_P"L<]%^@X_&NU\.Z%;^'])CM(E!
MD(#328Y=^_X>E`%57\8NF_R='C/_`#S+R,?S%8NI^-M=T"54U?08@K?=DAF.
MQOH<'\J[FJ>K:9!K&F3V-PH*2J0"1]T]B/H:`+,$HGMXYEZ2(&'XC-/JKI=M
M-9:5:VMPZO+#$L;,O0D#&:M4`9WB#5TT/1;B_8!FC7$:G^)CP!2Z#JJZUHMM
MJ"@*94^=1_"PX(_.N<\5VTOB;5FT2W<A+&W:XE([RD81?\^M9WPNU0J;O2)3
M@C]]&#V[,/Y4`>B4444`<;9JA(RV/PK=@?R[63RYBY5"0I3IQ7.VT@1AD9]J
MW;.Z.W+,$C'\*C[WM7RF73BM-CNK)D>GS)@$G.>M:(G5YU"]QSQFJ)TV)I`\
M$QA\P%O+(R`*GB6&U0-YC,9!_K/[I^E>C0]K!<LMEU_K4QERO5%:_P!CDDSE
MC[KTJ/P^`-0FP<_N_3W%,OKDDD2A6/\`>'4_C2^'#NU"8C_GG_45QQG&6-A;
MN:6:ILZ.F331V\$D\K;8XU+,3V`Y-/KEO'5Y(UE;:):G_2=4E$?'9,_,?Y?K
M7TQQF=X5\0Z0)=0U?4=2MX;J_FXC=^4C7A17,:]?V>G^-UU?2;J*>(NLY\IL
M@'HP/UY_.O5[;3+.TM8K>.WBVQ($&4'88KF/B+HL=QX>^V00HLEF^\[5`RAX
M/]#^%`'7031W,$<\3;HY%#J?4$9I]<E\.-5^W^'?LCMF6R;9_P``/*_U'X5U
MM`'EWQ4_Y#=G_P!>W_LQK>D\7WNB:):RW7AVY$(B15E$RE#P,9QTS6#\5/\`
MD-V?_7M_[,:]!M;2"^\.6]I<H'AFM45U/<;10!QVF6(^(5Y_:VIW*+;VS;%L
M8<Y7O\Q/K[5W\<:0QI%&@1$`5548``[5Y%!+>>`/%S1ON>W)PP_YZQ'H?J/Y
MBO6[>XBNK>.X@<212J&1AT(-`'D&G'[3\28S/R3J#$Y]0QQ_(5['7D?C"RG\
M.^,EU*)/W<LHN8CVW`Y9?S_G7JEA?0:E8PWMLX:*90RG^GUH`L4449P,G@4`
M%07MW%864UW.<1PH7;Z"J^D:O#K,$UQ;HPACF:)')XDV_P`0]JP?&T[WTVG^
M&[=B)+^4--C^&('G_/M0!4\(Z]H]M9W-_J.J6T=]J$[32JS\H,X5?P'\ZY6Y
MU"TT7Q[_`&CIUS'/:&82$Q'(VM]Y?U->MQV-I%&L:6T05`%`V#H*XSXEZ-&^
MD0ZC!"JM;/MDVKC*M_@<?G0!W*LKJ'4@JPR".XI:YKP%JO\`:?AF%7;,UH?)
M?/7`^Z?RQ^5=+0!QVIV$MA=-E3Y3,2C=L>E1PW)R`QXKLW1)$*.H93U##(JH
M=&TXG/V5/P)KYZKE$U4<J,K+LSKCB%:TD8D>H9E+D]B/H,5&]]F,IGW%;W]C
M:=_S[+^9H_L73O\`GU7\S5/`8QJW,OQ_R%[6GV.4EG9QC/%=!X>L)+>)[B52
MK2@!0>N*OPZ98P.'CMD##H2,X_.K5:X++'1J>UJ2NUL*I64H\L45=0N+NVM]
M]E8F\E)QY8D"8'J2:XHZ9XPD\4Q:_<:;;RF(%4MQ<*`JX(P#Z\YS7?U72^AD
MO&M4W&11EOEP%KVCF"RFN+BU62ZM#:2DG,1</C\1Q6;X@EU:6VGL;#1Q=)/"
M5,SSJBC((/!Y.*VJBCNH99Y($?,D7WQCI0!YOH'AKQAX<OOM=K:02!EVR1-.
MN''^/O7=)J&JG36G?1&6Z#;1;"X0[AZ[NF*TZ*`/-?$GASQ7XFU!;N73H+=4
M38D8N%)`SGD^O-=5H-QXA@BMK'4]'14C41FYBN%(``X)7K^5=!10!SGC3PU_
MPD.EY@5?MMO\T)/&[U4GW_G6/X9M/&7AZV^ROIL-U:YRL9N55D]<'T]J[.&^
MAGN7MX]Q:,9<E<`>U6*`,R]TR#Q#HXM]4LS$7&2F\%HF]0P[US%AH?B?PA,Z
MZ88M5T]VW&!FV./<9Z'Z5W5%`&`OB:[V?O/#.K+)_="*1^>ZLK66\8>(+9K2
MSTU=,MI!AVEG'F,/3CH*[2B@#G],M-0\.>&;.RM=/6^N4!\Q5F"*"23G)ZBL
M"UTSQ?#XI;7[K3;>X=E*>2MPHV+V"GV_QKOZ*`(;26:>U22XMS;2L/FB+!BO
MXC@UB>)O[8O;*ZTRQT=9XYX]OVB2X55&?]GKQ70T4`>;^'-`\8>&;QIH+*":
M*0`2PFX4;@.X/8UUXU;6L<^&I@?^OJ/_`!K9HH`****`"BBB@`HHHH`:[K&C
M.QPJC)-85K?O#%/J'V=I?.D^9LX"KT`'K6AK(E;3F2)6;>P#;1DA>](MO]J6
M&(1-%:0X(5A@R$=..PH`N2S"*+S""<]`.IJ#3KG[9`;CR!$68CCG<!WS4>L-
M-]D$,".QF8(Q09*KWJQ#$T=F(E41D+A0#T]*`()-2R9S!%YD=N/WCEL#/H/4
MU:CG22W6=<E67<..:QXH)SI2:=%&RRR$^<[#`49YY[U?OI!8:4PCZJHC3ZG@
M4`44U.Y4W-_Y9>U5P@4M@J!W`K8\U/)\[/R;=V?;&:R5M6GTZ#3HD=5X,[LN
M,=R/<YJYJ:2FP^SVZ$F0B/C^$=S^5`&=97LD-I<WRP&4R.7=BV`H[#W-;<,H
MF@24#`=0V#VK/:(3VYTR&&2*-&"N[+@%1R<>I-2:J9([)(H(W9694<1C)"=Z
M`"[U,00&:*$RKG:K9P&/MZU:>5HK<.Z$O@95?6LMUN;C5(5-LRPPKNC0CY0>
MQ)]O2KVJ&8V+QP(S22808[9ZF@"M;ZO-=0K)!8L_SX?#<*/ZU;OKP64#2;"Y
M`SC.!^=/M+9+2V2!.B#D^I[FJFH027UU#:;6%N/GE;L?04`,;6MB6TAMB$G.
M,[N?P'>I[:_>XO9;9K<Q^6H;.[/7L?0U6$3O=S7TD#;;92EO%CKCOBIM'BE2
MW:29"KRG>Y;[Q)]O2@"Y-.D(&[)9CA57DL:KVU[)<7LL'D;%A`W-NSR>U5&F
MNQ=7LJVTC2(-L3$?*JCT]2:GT:&2*SS(A5G.YB_WF8]?PH`T****`"BBB@`H
MHHH`****`"BBB@`HHHH`*Y_5=0)U*&%HP8X)`Q&?O&BB@#H`<@&BBB@`HHHH
7`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
